Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931587 | 0.82 | ALDH1A1 (0.46) | NUDT1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13723134 | 0.82 | TDP1 (0.50) | TSHRNUDT1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL14088925 | 0.82 | SMN1; SMN2 (0.53) | TSHRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23539171 | 0.81 | PPARA (0.47) | CYP2C9TSHRMAPTALDH1A1MEN1 | |
| SCHEMBL508228 | 0.79 | MAOB (0.46) | NUDT1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12250930 | 0.79 | CA1 (0.52) | CYP2C9TSHRCA12CA1CA2 | |
| SCHEMBL23202421 | 0.78 | NUDT1 (0.38) | NUDT1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL21538656 | 0.78 | PRKAB2 (0.43) | NUDT1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3793694 | 0.78 | CA1 (0.47) | CA1CA2KDM4EAPP | |
| SCHEMBL7027797 | 0.78 | DGAT1 (0.47) | CA1CA2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1466900-B1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | TAKAYAMA HIROAKI (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1466900-B1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | TAKAYAMA HIROAKI (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20050131242-A1 | 2-substituted vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1466900-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6596758-B1 | Treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds. | MERCK PATENT GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
| EP-1140893-B1 | BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS | MERCK PATENT GMBH (DE) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | VDR, CYP2R1, CYP24A1 | CYP2C9 292/4885TSHR 381/4885CA12 4097/4885 |
| US-20050131242-A1 | 2-substituted vitamin d derivatives | VDR, CYP2R1, CYP24A1 | CYP2C9 246/4885TSHR 328/4885CA12 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.